Match tier
Likely match
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
J
Joseph M. Beck
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Emory University (2007)
Unknown Researcher
1 h-index
9 pubs
630 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Joseph M. Beck's research focuses on the investigation of cancer immunotherapies, specifically examining the efficacy of dual blockade strategies targeting CTLA-4 and PD-1 in rare tumor types. His work includes contributions to phase II basket trials, such as the SWOG S1609 study, which evaluates this combined blockade in specific cancer cohorts, including vaginal cancer. Beck has published nine scholarly works, accumulating over 600 citations and an h-index of 1. His recent publications in 2025 and 2026 highlight the ongoing exploration of these advanced treatment modalities in challenging oncological cases.
Metrics
- h-index: 1
- Publications: 9
- Citations: 630
Selected Publications
-
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results (2026)
Collaboration Network
Top Collaborators
Young Kwang Chae
Northwestern University (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Josie Czeskleba
Fred Hutch Cancer Center (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Sandip Pravin Patel
University of San Diego (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Alex Mentor
Kaiser Permanente Lone Tree Medical Offices (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
William Robinson
Tulane University (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Nathaniel Jones
USA Mitchell Cancer Institute (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Murtuza Rampurwala
North Park University (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Aung Naing
The University of Texas MD Anderson Cancer Center (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Carolyn Moloney-Lineen
Northwestern University (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Liam Il‐Young Chung
Northwestern University (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Christine M. McLeod
Cancer Research And Biostatistics (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Helen X. Chen
National Cancer Institute (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Elad Sharon
Dana-Farber/Harvard Cancer Center (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Sara Threlkel
Fred Hutch Cancer Center (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Megan Othus
Fred Hutch Cancer Center (US)
1 shared publication
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Similar Researchers
Based on overlapping research topics
T Wonder NO Meridia
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
Mika Taylor
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
Teresa Evans
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
Shelby N. Bess
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
Alicia L. Graham
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers